“Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S53. doi:10.25251/skin.3.supp.53.